Zai Lab - ADR opened higher at $26.57, compared with its previous close of $26.42. In the last trading session, the stock traded between $25.84 and $26.75. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Zai Lab - ADR is now worth
$ 30.58
Resulting in a loss of
$ 69.42 (69.42%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.37 (-1.39%)
Day High
$26.75
Day Low
$25.84
Day Open
$26.57
Prev Close
$26.42
Volume
7,17,197
1W Return
14.10%
1M Return
6.08%
3M Return
0.18%
6M Return
32.99%
1Y Return
18.42%
Fundamentals
Market Cap ($ Mn)
3,260
PE Ratio
-
PB Ratio
4.82
PEG Ratio
-
ROE
-22.40%
ROCE
-24.99%
EPS (TTM)
$-0.04
Investment Returns
1 Week
14.10%
1 Month
6.08%
3 Months
0.18%
6 Months
32.99%
9 Months
36.90%
Financials
Quarterly
All values in $ Mn
106.5
Mar 25
110.0
Jun 25
116.1
Sep 25
127.6
Dec 25
106.3
Jun 26
108.2
Sep 26
Updates
14Oct
Zai Lab to present ZL-1503 clinical data at ACAAI 2026 meeting
Zai Lab presents Phase 1/1b data for ZL-1503 at ACAAI 2026. Trial involves healthy volunteers with PK and PD biomarker results. Poster session scheduled for November 13, 2026, in Phoenix.
29 days ago
6Aug
Zai Lab Q2 Results: EPS Misses Estimates as Sales Fall 3.84% YoY
Zai Lab's Q2 results show an EPS of $(0.46), missing estimates by 666.67% and worsening 24.32% YoY. Sales of $105.751M beat estimates by 0.41% but fell 3.84% from $109.977M last year.
3mo ago
22Jul
Zai Lab to announce Q2 2026 financial results on August 6
Zai Lab Limited will announce its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Participants must register in advance to join the call, with a replay available afterward on the company's website.
3mo ago
16Jun
Zai Lab wins EMA orphan drug status for zoci in lung cancer
Zai Lab Limited secured Orphan Drug Designation from the EMA for zocilurtatug pelitecan (zoci) to treat pulmonary neuroendocrine carcinomas. The designation follows a positive opinion from the COMP, citing the drug's potential advantage in treating relapsed or refractory small cell lung cancer. This milestone complements previous Fast Track and Orphan Drug designations from the U.S. FDA for both SCLC and extrapulmonary neuroendocrine carcinomas.
4mo ago
9Jun
Zai Lab secures China NMPA approval for TIVDAK to treat cervical cancer
Zai Lab Limited secured China NMPA approval for TIVDAK to treat recurrent or metastatic cervical cancer, based on Phase 3 trial data showing overall survival benefit. The therapy is the first antibody-drug conjugate approved for this indication in China, addressing a significant unmet need for patients with limited treatment options.
